Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients

NCT03469271 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2023-09-26

Study results available
· View outcomes & findings →

Summary

This research is intended to begin to explore the impact of inspiratory muscle resistance exercise and/or 1,25(OH)2D3 for improving respiratory muscle strength in cancer patients (subjects).

Conditions

Interventions

DRUG

1,25 (OH)2 D3

0.25 micrograms, taken daily for eight weeks, orally

OTHER

Inspiratory isometric resistance training

A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles.Participants in the active groups will breathe against a resistance set to generate 30% of maximal inspiratory pressure (PImax).

DRUG

Oral Placebo

Placebo will be created to mimic the appearance of the study drug

OTHER

Sham Inspiratory Isometric Resistance Training

A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles. Participants in the sham group will train daily against a resistance set to only 15% PImax.

DEVICE

Threshold Inspiratory Muscle Trainer (IMT)

A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles.

Sponsors & Collaborators

  • Andersen Foundation

    collaborator OTHER
  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Aminah Jatoi · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-25
Primary Completion
2020-05-21
Completion
2020-05-21
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03469271 on ClinicalTrials.gov